Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Feng Li has a total of 308 co-authors. Here are the top co-authors by number of shared publications:

  • David T. W. Wong

    School of Dentistry, University of California, Los Angeles, Los Angeles, USA

    17 shared publications
  • Zu-Chuan Zhang

    Key Laboratory of Proteomics, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, the Chinese Academy of Sciences Shanghai 200031, China

    8 shared publications
  • David Chia

    Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA

    6 shared publications
  • Xin-Xiu Yang

    Key Laboratory of Proteomics, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China

    6 shared publications
  • Yong Kim

    School of Dentistry, University of California Los Angeles, Los Angeles, CA 90095, USA

    6 shared publications
  • Zhen Li

    Key Laboratory of Proteomics, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, The Chinese Academy of Sciences, 320 Yue-yang Road, Shanghai 200031, PR China

    6 shared publications

Latest Publications

  • Extracellular Particles to Track Cancer Biomarkers from Tissue to Biofluids

    by K.T. Nguyen, J. Xia, C. Chang, A. Ghosh, M D Hade, X.Y. Rima, J.Y. An, S.E. Oh, B.H. Min, C.K. Nagaraj, et al.

    Liquid biopsies that analyze the molecular content of extracellular vesicles and particles (EVPs) are a formidable opportunity for early and late-stage cancer diagnosis. This study explores the potential of two advanced technologies: Bessel beam excitation separation technology (BEST) and multiparametric biochip assay (MBA), to track single EVP cargo from organs of pathology into biofluids such as plasma and saliva. Using gastric cancer (GC) as a disease model, we conducted high-throughput, multiparametric analyses of EVPs derived from plasma, saliva, and tissue samples from GC patients. Our findings demonstrate the feasibility of these techniques in isolating and characterizing EVPs, revealing consistent EVP morphology and size across biofluids. Furthermore, differential expression patterns of the developed and validated salivary GC biomarkers, miR-140-5p and miR-301a-3p, were observed in the biofluids of GC patients, supporting the diagnostic relevance of these cargo molecules. Notably, saliva emerged as the most promising biofluid for GC diagnosis, achieving superior receiver-operating characteristic curve values compared with plasma and tissue. This study highlights the role of BEST and MBA in advancing single-EVP analysis and elucidating EVP trafficking, paving the way for future diagnostic applications of EVP cargo.


  • Open Access

    Rapid and comprehensive detection of viral antibodies and nucleic acids via an acoustofluidic integrated molecular diagnostics chip: AIMDx

    by Jiao Qian, Jianping Xia, Samantha Chiang, Jessica F. Liu, Ke Li, Feng Li, Fang Wei, Mohammad Aziz, Yong Kim, Vinson Go, et al.

    Precise and rapid disease detection is critical for controlling infectious diseases like COVID-19. Current technologies struggle to simultaneously identify viral RNAs and host immune antibodies due to limited integration of sample preparation and detection. Here, we present acoustofluidic integrated molecular diagnostics (AIMDx) on a chip, a platform enabling high-speed, sensitive detection of viral immunoglobulins [immunoglobulin A (IgA), IgG, and IgM] and nucleic acids. AIMDx uses acoustic vortexes and Gor’kov potential wells at a 1/10,000 subwavelength scale for concurrent isolation of viruses and antibodies while excluding cells, bacteria, and large (>200 nanometers) vesicles from saliva samples. The chip facilitates on-chip viral RNA enrichment, lysis in 2 minutes, and detection via transcription loop–mediated isothermal amplification, alongside electrochemical sensing of antibodies, including mucin-masked IgA. AIMDx achieved nearly 100% recovery of viruses and antibodies, a 32-fold RNA detection improvement, and an immunity marker sensitivity of 15.6 picograms per milliliter. This breakthrough provides a transformative tool for multiplex diagnostics, enhancing early infectious disease detection.


  • Open Access

    Exosomal miR-151-3p in saliva: A potential non-invasive marker for gastric cancer diagnosis and prognosis modulated by Sijunzi decoction (SJZD) in mice

    by Ping Yang, Huijun Lei, Yue Fu, Cheng Chen, Li Tang, Shuaishuai Xia, Yan Guo, Guangyu Chen, Mengzhou Xie, Jingjing Yang, et al.


  • Open Access

    Multi-faceted attributes of salivary cell-free DNA as liquid biopsy biomarkers for gastric cancer detection

    by Neeti Swarup, Jordan Cheng, Irene Choi, You Jeong Heo, Misagh Kordi, Mohammad Aziz, Akanksha Arora, Feng Li, David Chia, Fang Wei, et al.

    Background: Recent advances in circulating cell-free DNA (cfDNA) analysis from biofluids have opened new avenues for liquid biopsy (LB). However, current cfDNA LB assays are limited by the availability of existing information on established genotypes associated with tumor tissues. Certain cancers present with a limited list of established mutated cfDNA biomarkers, and thus, nonmutated cfDNA characteristics along with alternative biofluids are needed to broaden the available cfDNA targets for cancer detection. Saliva is an intriguing and accessible biofluid that has yet to be fully explored for its clinical utility for cancer detection. Methods: In this report, we employed a low-coverage single stranded (ss) library NGS pipeline “Broad-Range cell-free DNA-Seq” (BRcfDNA-Seq) using saliva to comprehensively investigate the characteristics of salivary cfDNA (ScfDNA). The identification of cfDNA features has been made possible by applying novel cfDNA processing techniques that permit the incorporation of ultrashort, ss, and jagged DNA fragments. As a proof of concept using 10 gastric cancer (GC) and 10 noncancer samples, we examined whether ScfDNA characteristics, including fragmentomics, end motif profiles, microbial contribution, and human chromosomal mapping, could differentiate between these two groups. Results: Individual and integrative analysis of these ScfDNA features demonstrated significant differences between the two cohorts, suggesting that disease state may affect the ScfDNA population by altering nuclear cleavage or the profile of contributory organism cfDNA to total ScfDNA. We report that principal component analysis integration of several aspects of salivary cell-free DNA fragmentomic profiles, genomic element profiles, end-motif sequence patterns, and distinct oral microbiome populations can differentiate the two populations with a p value of < 0.0001 (PC1). Conclusion: These novel features of ScfDNA characteristics could be clinically useful for improving saliva-based LB detection and the eventual monitoring of local or systemic diseases.


  • Open Access

    Single-Droplet Microsensor for Ultra-Short Circulating EFGR Mutation Detection in Lung Cancer Based on Multiplex EFIRM Liquid Biopsy

    by Fang Wei, Peter Yu, Jordan Cheng, Feng Li, David Chia, David T. W. Wong

    Liquid biopsy is a rapidly emerging field that involves the minimal/non-invasive assessment of signature somatic mutations through the analysis of circulating tumor DNA (ctDNA) shed by tumor cells in bodily fluids. Broadly speaking, the unmet need in liquid biopsy lung cancer detection is the lack of a multiplex platform that can detect a mutation panel of lung cancer genes using a minimum amount of sample, especially for ultra-short ctDNA (usctDNA). Here, we developed a non-PCR and non-NGS-based single-droplet-based multiplexing microsensor technology, “Electric-Field-Induced Released and Measurement (EFIRM) Liquid Biopsy” (m-eLB), for lung cancer-associated usctDNA. The m-eLB provides a multiplexable assessment of usctDNA within a single droplet of biofluid in only one well of micro-electrodes, as each electrode is coated with different probes for the ctDNA. This m-eLB prototype demonstrates accuracy for three tyrosine-kinase-inhibitor-related EGFR target sequences in synthetic nucleotides. The accuracy of the multiplexing assay has an area under the curve (AUC) of 0.98 for L858R, 0.94 for Ex19 deletion, and 0.93 for T790M. In combination, the 3 EGFR assay has an AUC of 0.97 for the multiplexing assay.


  • Open Access

    Evaluating Pre-Analytical Variables for Saliva Cell-Free DNA Liquid Biopsy

    by Blake Salfer, Daisy Havo, Skyllar Kuppinger, David T. W. Wong, Feng Li, Liying Zhang

    Liquid biopsy utilizing cell-free DNA (cfDNA) has become an emergent field of study for cancer screening and monitoring. While blood-based liquid biopsy has been investigated extensively, there are advantages to using other body fluids. Using saliva is noninvasive, repeatable, and it may be enriched with cfDNA from certain cancer types. However, the lack of standardization in the pre-analytical phase of saliva-based testing is a concern. In this study, we evaluated pre-analytical variables that impact cfDNA stability in saliva specimens. Using saliva from healthy individuals, we tested different collection devices and preservatives and their effects on saliva cfDNA recovery and stability. Novosanis’s UAS preservative helped stabilize cfDNA at room temperature for up to one week. Our study provides useful information for further improvements in saliva collection devices and preservatives.


  • Open Access

    Single Droplet Microsensor for Ultra-Short Circulating EFGR Mutations Detection in Lung Cancer Based on Multiplex EFIRM Liquid Biopsy

    by Fang Wei, Peter Yu, Jordan Cheng, Feng Li, David Chia, David T.W. Wong

    Liquid biopsy is a rapidly emerging field which involves the minimal/non-invasive assessment of signature somatic mutations through analysis of circulating tumor DNA (ctDNA) shed by tumor cells in bodily fluids. The broad, unmet need for liquid biopsy lung cancer detection is the lack of multiplex platform that can detect a mutation panel of lung cancer genes using minimum amount of sample, especially for ultra-short ctDNA (usctDNA). Here we developed a non-PCR and non-NGS-based single droplet based multiplexing microsensor technology “Electric Field-Induced Released and Measurement (EFIRM) Liquid Biopsy” (m-eLB) for lung can-cer-associated usctDNA. The m-eLB provides multiplexable assessment of usctDNA within a single droplet of biofluid in only one well of micro-electrodes, as each electrode coated with dif-ferent probes for the ctDNA. In this m-eLB prototype, it demonstrates accuracy for 3 tyrosine ki-nase inhibitor related EGFR target sequences in synthetic nucleotides. The accuracy for the multi-plexing assay has an AUC of 0.98 for L858R, Ex19del, AUC of 0.94 for Ex19 deletion and AUC of 0.93 for T790M. By combining the 3 EGFR assay together, the AUC was 0.97 for the multiplexing assay.

  • Proficiency Testing of Epidermal Growth Factor Receptor Mutations Detection in Saliva Using Spectrum Saliva Collector (SDNA-1000) and Preservative Solution Detected by Electric Field-Induced Release and Measurement

    by Feng Li, Fang Wei, Tristan R. Grogan, David E. Elashoff, David Vu, David J. Vigerust, Rohit Gupta, David T.W. Wong

    Biopreservation and Biobanking


  • Open Access

    Performance of Salivary Extracellular RNA Biomarker Panels for Gastric Cancer Differs between Distinct Populations

    by Karolina Elżbieta Kaczor-Urbanowicz, Mustafa Saad, Tristan R. Grogan, Feng Li, You Jeong Heo, David Elashoff, Robert S. Bresalier, David T. W. Wong, Yong Kim

    Gastric cancer (GC) has the fifth highest incidence among cancers and is the fourth leading cause of cancer-related death GC has predominantly a higher number of cases in certain ethnic groups such as the Korean population. GC found at an early stage is more treatable and has a higher survival rate as compared with GC found at a late stage. However, a diagnosis of GC is often delayed due to the lack of early symptoms and available screening programs in United States. Extracellular RNA (exRNA) is an emerging paradigm; exRNAs have the potential to serve as biomarkers in panels aimed at early detection of cancer. We previously reported the successful use of a panel of salivary exRNA for detecting GC in a high-prevalence Korean cohort, and that genetic changes reflected cancer-associated salivary exRNA changes. The current study is a case-control study of salivary exRNA biomarkers for detecting GC in an ethnically distinct U.S. cohort. A model constructed for the U.S. cohort combined demographic characteristics and salivary miRNA and mRNA biomarkers for GC and yielded an area under the receiver operating characteristic (ROC) curve (AUC) of 0.78. However, the constituents of this model differed from that constructed for the Korean cohort, thus, emphasizing the importance of population-specific biomarker development and validation.


  • Open Access

    Plasma contains ultrashort single-stranded DNA in addition to nucleosomal cell-free DNA

    by Jordan Cheng, Marco Morselli, Wei-Lun Huang, You Jeong Heo, Thalyta Pinheiro-Ferreira, Feng Li, Fang Wei, David Chia, Yong Kim, Hua-Jun He, et al.